article thumbnail

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Health Populi

As the Harvard Chan-POLITICO study points out, prescription drug costs are top-of-mind for health consumers in America. First, a Wall Street Journal profile of Bluebird Bio , a biotech firm that plans to sell gene-replacement therapy extending annual payments to patients based on whether the drug is effective.

BioTech 160
article thumbnail

Will Technology Cure Americans’ Health Care System Ills? Considering Google and Ascension Health’s Data Deal

Health Populi

What’s underneath that macro “healthcare” index number of 67 is a precipitous decline in the past year for Americans’ trust in hospitals, compared with biotech, pharma, consumer healthcare, and even health insurance — all of which grew in trust between 2018 and 2019, but not so with the hospital segment of U.S.

BioTech 160
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Matter of Trust, Perception, Risk, and Uncertainty – The Big Issues Raised by the Acquisition of PatientsLikeMe and Other Patient Data Transactions

Health Populi

To address that challenge, in 2017 PLM secured a $100 million (controlling interest) investment from iCarbonX , a Chinese company that is amassing patient data to discover cures for disease. When this occurred, it didn’t cause more than a ripple of interest outside biotech. But the U.S. citizens’ personal data.

article thumbnail

Most Americans Across Party ID Favor U.S. Government Negotiation to Lower Rx Drug Costs

Health Populi

The Kaiser Family Foundation has been tracking this topic for a few years, and this month, their March 2019 Health Tracking Poll shows vast majorities of Democrats, Independents and Republicans all share these sentiments. There’s little Americans, by political party, agree upon in 2019.